Wilms Tumor 1 (WT1) (N-Term) Peptid
WT1
Reaktivität: Human
Wirt: Synthetic
WB, BP
-
- Target Alle WT1 Produkte
- WT1 (Wilms Tumor 1 (WT1))
- Protein Region
- N-Term
- Spezies
- Human
-
Quelle
- Synthetic
- Applikation
- Western Blotting (WB), Blocking Peptide (BP)
- Sequenz
- DFAPPGASAY GSLGGPAPPP APPPPPPPPP HSFIKQEPSW GGAEPHEEQC
- Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-WT1 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- WT1 (Wilms Tumor 1 (WT1))
- Synonyme
- AWT1 Peptide, EWS-WT1 Peptide, GUD Peptide, NPHS4 Peptide, WAGR Peptide, WIT-2 Peptide, WT33 Peptide, CWT1 Peptide, WT1 Peptide, XWT1a Peptide, wt-1 Peptide, wt1 Peptide, xWT1 Peptide, WT-1 Peptide, gud Peptide, wagr Peptide, wt33 Peptide, xwt1 Peptide, wit-2 Peptide, si:ch211-160j6.3 Peptide, zgc:152697 Peptide, D630046I19Rik Peptide, Wt-1 Peptide, XWT1b Peptide, XeWT1 Peptide, Wilms tumor 1 Peptide, Wilms tumor 1 S homeolog Peptide, wilms tumor 1b Peptide, Wilms tumor protein Peptide, Wilms tumor 1 homolog Peptide, Wilms tumor 1 L homeolog Peptide, WT1 Peptide, wt1.S Peptide, wt1 Peptide, wt1b Peptide, Wt1 Peptide, wt1.L Peptide
- Hintergrund
-
WT1 is a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilm's tumors. Multiple transcript variants, resulting from alternative splicing at two coding exons, have been well characterized. There is also evidence for the use of non-AUG (CUG) translation initiation site upstream of, and in-frame with the first AUG, leading to additional isoforms.
Protein Size: 432 - Gen-ID
- 7490
-
Sie sind hier:
